A new cancer treatment using injections of radium-223 was found to extend the life of prostate cancer patients by an average of 15 weeks, by targeting bone metastases.
The radium treatment targets cancer cells and has a short range, leaving healthy cells mostly unharmed and causing minimal side effects.
A trial of 921 men showed that the treatment could replace docetaxel, which is currently used to treat bone metastases but unsuitable for frail patients.
Read more at The Royal Marsden NHS Foundation Trust